Want to see XAIR full AI Analyst Report?
XAIR Stock Chart & Stats
$5.36
$0.21(3.97%)
At close: 4:00 PM EDT
$5.36
$0.21(3.97%)
Day’s Range― - ―
52-Week Range$4.88 - $95.60
Previous Close$5.37
Volume15.95K
Average Volume (3M)18.32K
Market Cap
$4.94M
Enterprise Value$15.66
Total Cash (Recent Filing)$9.81M
Total Debt (Recent Filing)$1.43M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 16, 2026EPS Estimate
-2.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-53.60
Shares Outstanding957,631
10 Day Avg. Volume28,112
30 Day Avg. Volume18,318
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.70
Price to Sales (P/S)14.92
P/FCF Ratio-5.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.78
Revenue Forecast (FY)$12.70M
Bulls Say, Bears Say
Bulls Say
Revenue ScalingRevenue is progressing from a negligible base as LungFit adoption expands in the U.S. and internationally. Sustained commercial uptake would improve operating leverage and create a larger installed base for recurring consumables revenue.
Commercial AccessBroader GPO access can reduce procurement friction and place LungFit in more hospitals, while international distribution expands the addressable market. These channels can support durable adoption rather than relying only on direct selling.
Improving Unit EconomicsImproving gross margin and lower R&D spending indicate progress toward a more efficient commercialization model. If margins continue to rise with volume, the company could narrow losses as revenue scales without proportionate expense growth.
Bears Say
Severe UnprofitabilityThe current revenue base remains far below the scale needed to absorb operating costs, leaving exceptionally weak profitability. Large losses increase the time and capital required to reach breakeven and make execution dependent on rapid adoption.
Cash Burn And Thin EquityPersistent cash consumption and limited equity provide a narrow financial cushion. Until operations generate cash, Beyond Air may need repeated external funding, exposing the business to financing costs, dilution, or constrained investment in growth.
Regulatory And Dilution RiskGen II is central to the longer-term growth outlook, but FDA delays could defer commercialization and projected revenue. Funding the intervening period through warrant-linked financing also creates potential dilution and execution risk.
Beyond Air News
XAIR FAQ
What was Beyond Air Inc’s price range in the past 12 months?
Beyond Air Inc lowest stock price was $4.88 and its highest was $95.60 in the past 12 months.
What is Beyond Air Inc’s market cap?
Beyond Air Inc’s market cap is $4.94M.
When is Beyond Air Inc’s upcoming earnings report date?
Beyond Air Inc’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Beyond Air Inc’s earnings last quarter?
Beyond Air Inc released its earnings results on Aug 13, 2026. The company reported -$11 earnings per share for the quarter, missing the consensus estimate of -$10.8 by -$0.2.
Is Beyond Air Inc overvalued?
According to Wall Street analysts Beyond Air Inc’s price is currently Overvalued.
Does Beyond Air Inc pay dividends?
Beyond Air Inc does not currently pay dividends.
What is Beyond Air Inc’s EPS estimate?
Beyond Air Inc’s EPS estimate is -2.73.
How many shares outstanding does Beyond Air Inc have?
Beyond Air Inc has 957,631 shares outstanding.
What happened to Beyond Air Inc’s price movement after its last earnings report?
Beyond Air Inc reported an EPS of -$11 in its last earnings report, missing expectations of -$10.8. Following the earnings report the stock price went up 14.38%.
Which hedge fund is a major shareholder of Beyond Air Inc?
Currently, no hedge funds are holding shares in XAIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air Inc
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive, growth-oriented outlook: management strengthened the balance sheet via a financing, secured important commercial partnerships (including a third national GPO), expanded international distribution, and showed improving unit economics (gross margin up to 13%) while reducing R&D spend. The company reaffirmed 2026 guidance and provided an ambitious multi‑year revenue target for 2027 tied to the potential Gen II LungFit PH launch. Key risks highlighted include flat current revenue, ongoing net losses and cash burn, increased other expense, and regulatory timing uncertainty for Gen II approval. On balance, the positives around financing, commercial traction, margin improvement, and a doubled pipeline outweigh the near-term operational and regulatory risks.View all XAIR earnings summariesXAIR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
62.97% Insiders
1.56% Mutual Funds
― Other Institutional Investors
35.04% Public Companies and
Individual Investors